Abstract
Toxic iron species in lower-risk myelodysplastic syndrome patients: course of disease and effects on outcome
Highlights
Red blood cell transfusions (RBCT) remain the cornerstone of supportive care in lower-risk myelodysplastic syndrome (LRMDS) [1]
Males Females Age 35–44 45–54 55–64 65–74 75+ Mean Median MDS diagnosis RCMD RARS RA RAEB-1 RCMD-RS 5q-syndrome MDS-U Group NonRS-TI NonRS-TD ring sideroblasts were transfusion-independent (RS-TI) ring sideroblasts were transfusion-dependent patients (RS-TD) IPSS-R category Very low/low Intermediate High/very high Not known IPSS category Low risk Intermed-1 Intermed-2 Not known Karnofsky performance status Able to work and normal activity Unable to work Unable to care for self Not known Comorbidity index Low risk Intermediate risk High risk EQ5D index score Mean Median (p10–p90)
The results of this study suggest that LRMDS patients who are transfusion-dependent and have a MDS subtype with ring sideroblasts have the highest levels for markers that reflect iron toxicity
Summary
The aim of this study is twofold: (1) describe iron and oxidative stress parameters over time in LRMDS patients and (2) to assess their effect on overall and progression-free survival
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
